Linked Life Data

9632271

Source:http://linkedlifedata.com/resource/pubmed/id/9632271

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9632271rdf:typepubmed:Citationlld:pubmed
pubmed-article:9632271lifeskim:mentionsumls-concept:C0040732lld:lifeskim
pubmed-article:9632271lifeskim:mentionsumls-concept:C0038250lld:lifeskim
pubmed-article:9632271lifeskim:mentionsumls-concept:C0204727lld:lifeskim
pubmed-article:9632271lifeskim:mentionsumls-concept:C0205409lld:lifeskim
pubmed-article:9632271lifeskim:mentionsumls-concept:C1332710lld:lifeskim
pubmed-article:9632271lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:9632271lifeskim:mentionsumls-concept:C0205100lld:lifeskim
pubmed-article:9632271lifeskim:mentionsumls-concept:C0007616lld:lifeskim
pubmed-article:9632271lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:9632271lifeskim:mentionsumls-concept:C1998793lld:lifeskim
pubmed-article:9632271pubmed:issue10lld:pubmed
pubmed-article:9632271pubmed:dateCreated1998-8-6lld:pubmed
pubmed-article:9632271pubmed:abstractTextPeripheral stem cells were mobilized and collected in 26 pediatric patients with malignant diseases. A total of 47 leukaphereses were performed in the 26 patients. The mean number of nucleated cells collected was 4.5 +/- 2.6 x 10(8)/kg and the number of CD34+ progenitors collected was 6.7 +/- 6.8 x 10(6)/kg. CD34-positive selection was performed using a two-step method of magnetic-activated cell sorting (MACS) in 24 patients or a combination of an immunoaffinity column and MACS in two patients. The purity of the positively selected CD34+ progenitors was 98.8 +/- 0.7% and the number of isolated CD34+ cells was 6.5 +/- 5.9 x 10(6)/kg. Thus, the mean recovery of CD34+ cells was 93 +/- 10%. In 22 of the 26 patients, high-dose chemotherapy was performed with subsequent reinfusion of the highly purified CD34+ cells. In all 22 patients, a normal hematopoietic reconstitution was seen with a mean time of 12.4 +/- 2.7 days to reach >0.5 x 10(9)/l neutrophils (range 8-19 days). The time to reach independence from platelet transfusion was 31.6 +/- 17.0 days (range 16-78 days). There were no transplant-related deaths. In summary, we have shown that mobilized peripheral CD34+ progenitors can be highly purified with a good recovery, and that reinfusion of these cells after high-dose chemotherapy results in a rapid, complete and sustained engraftment. We conclude that this method can be used for purging in any CD34-negative malignancies and for autologous T and B cell depletion in the treatment of autoimmune diseases with high-dose immunoablative therapy.lld:pubmed
pubmed-article:9632271pubmed:languageenglld:pubmed
pubmed-article:9632271pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9632271pubmed:citationSubsetIMlld:pubmed
pubmed-article:9632271pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9632271pubmed:statusMEDLINElld:pubmed
pubmed-article:9632271pubmed:monthMaylld:pubmed
pubmed-article:9632271pubmed:issn0268-3369lld:pubmed
pubmed-article:9632271pubmed:authorpubmed-author:NiethammerDDlld:pubmed
pubmed-article:9632271pubmed:authorpubmed-author:LaneRRlld:pubmed
pubmed-article:9632271pubmed:authorpubmed-author:TaylorGGlld:pubmed
pubmed-article:9632271pubmed:authorpubmed-author:NeuSSlld:pubmed
pubmed-article:9632271pubmed:authorpubmed-author:KlingebielTTlld:pubmed
pubmed-article:9632271pubmed:authorpubmed-author:Handgretinger...lld:pubmed
pubmed-article:9632271pubmed:authorpubmed-author:SchummMMlld:pubmed
pubmed-article:9632271pubmed:authorpubmed-author:KoscielnakEElld:pubmed
pubmed-article:9632271pubmed:issnTypePrintlld:pubmed
pubmed-article:9632271pubmed:volume21lld:pubmed
pubmed-article:9632271pubmed:ownerNLMlld:pubmed
pubmed-article:9632271pubmed:authorsCompleteYlld:pubmed
pubmed-article:9632271pubmed:pagination987-93lld:pubmed
pubmed-article:9632271pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9632271pubmed:meshHeadingpubmed-meshheading:9632271-...lld:pubmed
pubmed-article:9632271pubmed:meshHeadingpubmed-meshheading:9632271-...lld:pubmed
pubmed-article:9632271pubmed:meshHeadingpubmed-meshheading:9632271-...lld:pubmed
pubmed-article:9632271pubmed:meshHeadingpubmed-meshheading:9632271-...lld:pubmed
pubmed-article:9632271pubmed:meshHeadingpubmed-meshheading:9632271-...lld:pubmed
pubmed-article:9632271pubmed:meshHeadingpubmed-meshheading:9632271-...lld:pubmed
pubmed-article:9632271pubmed:meshHeadingpubmed-meshheading:9632271-...lld:pubmed
pubmed-article:9632271pubmed:meshHeadingpubmed-meshheading:9632271-...lld:pubmed
pubmed-article:9632271pubmed:meshHeadingpubmed-meshheading:9632271-...lld:pubmed
pubmed-article:9632271pubmed:meshHeadingpubmed-meshheading:9632271-...lld:pubmed
pubmed-article:9632271pubmed:meshHeadingpubmed-meshheading:9632271-...lld:pubmed
pubmed-article:9632271pubmed:meshHeadingpubmed-meshheading:9632271-...lld:pubmed
pubmed-article:9632271pubmed:year1998lld:pubmed
pubmed-article:9632271pubmed:articleTitleIsolation and transplantation of autologous peripheral CD34+ progenitor cells highly purified by magnetic-activated cell sorting.lld:pubmed
pubmed-article:9632271pubmed:affiliationChildren's University Hospital, University of Tuebingen, Germany.lld:pubmed
pubmed-article:9632271pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9632271pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9632271lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9632271lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9632271lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9632271lld:pubmed